# Amesite Inc.: financial statements, quarterly

AMST · Nasdaq · CIK 1807166 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/amst.md) · [Financials](/companies/amst/financials.md) · [Filings](/companies/amst/filings.md) · [Insiders](/companies/amst/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amst/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [63.3](/filings/0001213900-25-000445.md) | [41.4](/filings/0001213900-25-011338.md) | [34.3](/filings/0001213900-25-044301.md) | [27.8 d](/filings/0001213900-25-093213.md) | [11.3](/filings/0001213900-25-102257.md) | [12.8](/filings/0001213900-26-012916.md) | [30.7](/filings/0001213900-26-058512.md) | [55.8 d](/filings/0001213900-26-102676.md) | [94.3](/filings/0001213900-25-102257.md) | [108](/filings/0001213900-26-012916.md) | [83.3](/filings/0001213900-26-058512.md) | [79.1 d](/filings/0001213900-26-102676.md) |
| Research and development | $k | [333](/filings/0001213900-25-000445.md) | [331](/filings/0001213900-25-011338.md) | [224](/filings/0001213900-25-044301.md) | [186 d](/filings/0001213900-25-093213.md) | [140](/filings/0001213900-25-102257.md) | [212](/filings/0001213900-26-012916.md) | [172](/filings/0001213900-26-058512.md) | [168 d](/filings/0001213900-26-102676.md) | [103](/filings/0001213900-25-102257.md) | [165](/filings/0001213900-26-012916.md) | [134](/filings/0001213900-26-058512.md) | [212 d](/filings/0001213900-26-102676.md) |
| Operating income | $k | [(950)](/filings/0001213900-25-000445.md) | [(956)](/filings/0001213900-25-011338.md) | [(1,464)](/filings/0001213900-25-044301.md) | [(1,210) d](/filings/0001213900-25-093213.md) | [(927)](/filings/0001213900-25-102257.md) | [(1,131)](/filings/0001213900-26-012916.md) | [(688)](/filings/0001213900-26-058512.md) | [(858) d](/filings/0001213900-26-102676.md) | [(662)](/filings/0001213900-25-102257.md) | [(745)](/filings/0001213900-26-012916.md) | [(684)](/filings/0001213900-26-058512.md) | [(1,052) d](/filings/0001213900-26-102676.md) |
| Net income | $k | [(891)](/filings/0001213900-25-044301.md) | [(906)](/filings/0001213900-25-044301.md) | [(1,426)](/filings/0001213900-25-044301.md) | [(1,181) d](/filings/0001213900-25-093213.md) | [(908)](/filings/0001213900-26-058512.md) | [(1,122)](/filings/0001213900-26-058512.md) | [(663)](/filings/0001213900-26-058512.md) | [(924) d](/filings/0001213900-26-102676.md) | [(642)](/filings/0001213900-26-058512.md) | [(733)](/filings/0001213900-26-058512.md) | [(678)](/filings/0001213900-26-058512.md) | [(1,043) d](/filings/0001213900-26-102676.md) |
| Diluted EPS | $ per share | [(0.35)](/filings/0001213900-25-000445.md) | [(0.36)](/filings/0001213900-25-011338.md) | [(0.56)](/filings/0001213900-25-044301.md) | not reported | [(0.34)](/filings/0001213900-25-102257.md) | [(0.40)](/filings/0001213900-26-012916.md) | [(0.16)](/filings/0001213900-26-058512.md) | not reported | [(0.14)](/filings/0001213900-25-102257.md) | [(0.16)](/filings/0001213900-26-012916.md) | [(0.15)](/filings/0001213900-26-058512.md) | not reported |
| Basic EPS | $ per share | [(0.35)](/filings/0001213900-25-000445.md) | [(0.36)](/filings/0001213900-25-011338.md) | [(0.56)](/filings/0001213900-25-044301.md) | not reported | [(0.34)](/filings/0001213900-25-102257.md) | [(0.40)](/filings/0001213900-26-012916.md) | [(0.16)](/filings/0001213900-26-058512.md) | not reported | [(0.14)](/filings/0001213900-25-102257.md) | [(0.16)](/filings/0001213900-26-012916.md) | [(0.15)](/filings/0001213900-26-058512.md) | not reported |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [4,637](/filings/0001213900-23-086169.md) | [3,663](/filings/0001213900-25-011338.md) | [2,973](/filings/0001213900-25-044301.md) | [2,071](/filings/0001213900-25-093213.md) | [1,435](/filings/0001213900-25-000445.md) | [520](/filings/0001213900-25-011338.md) | [2,859](/filings/0001213900-25-044301.md) | [2,333](/filings/0001213900-26-102676.md) | [1,830](/filings/0001213900-25-102257.md) | [1,165](/filings/0001213900-26-012916.md) | [641](/filings/0001213900-26-058512.md) | [2,299](/filings/0001213900-26-102676.md) |
| Current assets | $k | [4,732](/filings/0001213900-23-086169.md) | [3,858](/filings/0001213900-24-014049.md) | [3,153](/filings/0001213900-24-041800.md) | [2,505](/filings/0001213900-25-093213.md) | [2,432](/filings/0001213900-25-011338.md) | [1,445](/filings/0001213900-25-011338.md) | [3,139](/filings/0001213900-25-044301.md) | [2,434](/filings/0001213900-26-102676.md) | [1,906](/filings/0001213900-25-102257.md) | [1,332](/filings/0001213900-26-012916.md) | [822](/filings/0001213900-26-058512.md) | [2,413](/filings/0001213900-26-102676.md) |
| Total assets | $k | [5,512](/filings/0001213900-23-086169.md) | [4,552](/filings/0001213900-24-014049.md) | [3,835](/filings/0001213900-24-041800.md) | [3,314](/filings/0001213900-25-093213.md) | [3,171](/filings/0001213900-25-011338.md) | [2,136](/filings/0001213900-25-011338.md) | [3,809](/filings/0001213900-25-044301.md) | [3,097](/filings/0001213900-26-102676.md) | [2,596](/filings/0001213900-25-102257.md) | [1,998](/filings/0001213900-26-012916.md) | [1,492](/filings/0001213900-26-058512.md) | [3,030](/filings/0001213900-26-102676.md) |
| Current liabilities | $k | [263](/filings/0001213900-23-086169.md) | [176](/filings/0001213900-24-014049.md) | [212](/filings/0001213900-24-041800.md) | [798](/filings/0001213900-25-093213.md) | [843](/filings/0001213900-25-000445.md) | [889](/filings/0001213900-25-011338.md) | [211](/filings/0001213900-25-044301.md) | [359](/filings/0001213900-26-102676.md) | [428](/filings/0001213900-25-102257.md) | [490](/filings/0001213900-26-012916.md) | [190](/filings/0001213900-26-058512.md) | [376](/filings/0001213900-26-102676.md) |
| Shareholders' equity | $k | [5,249](/filings/0001213900-25-044301.md) | [4,376](/filings/0001213900-25-044301.md) | [3,623](/filings/0001213900-25-044301.md) | [2,516](/filings/0001213900-26-102676.md) | [2,328](/filings/0001213900-26-058512.md) | [1,247](/filings/0001213900-26-058512.md) | [3,598](/filings/0001213900-26-058512.md) | [2,739](/filings/0001213900-26-102676.md) | [2,168](/filings/0001213900-26-058512.md) | [1,508](/filings/0001213900-26-058512.md) | [1,302](/filings/0001213900-26-058512.md) | [2,654](/filings/0001213900-26-102676.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(659)](/filings/0001213900-25-000445.md) | [(919) d](/filings/0001213900-25-011338.md) | [(582) d](/filings/0001213900-25-044301.md) | [(654) d](/filings/0001213900-25-093213.md) | [(488)](/filings/0001213900-25-102257.md) | [(850) d](/filings/0001213900-26-012916.md) | [(677) d](/filings/0001213900-26-058512.md) | [(439) d](/filings/0001213900-26-102676.md) | [(416)](/filings/0001213900-25-102257.md) | [(621) d](/filings/0001213900-26-012916.md) | [(449) d](/filings/0001213900-26-058512.md) | [(661) d](/filings/0001213900-26-102676.md) |
| Capital expenditure | $k | not reported | not reported | [0.0 d](/filings/0001213900-25-044301.md) | [0.0 d](/filings/0001213900-25-093213.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2022 (2021-09-30) | Q2 FY2022 (2021-12-31) | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2024 (2024-03-31) | Q3 FY2025 (2025-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [21.6](/filings/0001213900-22-071308.md) | [22.0](/filings/0001213900-23-012931.md) | [27.4](/filings/0001213900-22-071308.md) | [30.3](/filings/0001213900-23-012931.md) | [2.5](/filings/0001213900-25-044301.md) | [4.1](/filings/0001213900-25-044301.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 6,549,851 at 2026-09-23, from the cover of the [10-K filed 2026-09-23](/filings/0001213900-26-102676.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.